- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SEC launches probe of ADAC financials
ADAC Laboratories continues to deal with fallout from the restatement of its financial results for 1996, 1997, and the first three quarters of 1998. The Securities and Exchange Commission this month initiated a formal investigation of the company’s
ADAC Laboratories continues to deal with fallout from the restatement of its financial results for 1996, 1997, and the first three quarters of 1998. The Securities and Exchange Commission this month initiated a formal investigation of the companys restatement.
News of the probe came out in ADACs annual 10-K report, filed with the SEC on Jan. 3. In the filing, ADAC stated that it is cooperating with the regulatory agency and that it cannot predict the outcome of the investigation.
In December 1998, ADAC announced that it would restate its financial results for the previous three years, provoking dramatic selling of its stock and shareholder lawsuits (SCAN 1/13/99). ADAC is contesting the suits, which were consolidated in April of last year.
In other ADAC news, the companys HealthCare Information Systems (HCIS) division and Agfa have signed an OEM agreement under which ADAC will distribute Agfas ADC computed radiography systems and Drystar hardcopy printers with its Envoi RIS and PACS systems. The deal is part of ADACs effort to offer a comprehensive RIS/PACS product to its customers, according to the Milpitas, CA-based company.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
